With Jakafi's patent cliff looming, Incyte looks to 2025 launches to bulk up revenue by decade's end

Incyte’s blockbuster JAK inhibitor Jakafi has been driving the company’s sales for years now, with this quarter being no different. But, as an end-of -decade patent cliff approaches, the company is turning to new potential growth drivers to make up for the looming loss.